Ascentage Pharma Group International (AAPG)
| Market Cap | 1.48B |
| Revenue (ttm) | 124.26M |
| Net Income (ttm) | -49.58M |
| Shares Out | 85.99M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AAPG
Ascentage Pharma Group is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. We are the only company in the world with activ... [Read more]
News
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American d...
Ascentage Pharma Group International IPO Registration Document (F-1)
Ascentage Pharma Group International has filed to go public with an IPO on the NASDAQ.